Drug Profile
XOMA 629
Alternative Names: 0.1% XMP 629 acetate gel; XMP 629; XMP.629 peptide; XOMA-629Latest Information Update: 26 Nov 2015
Price :
$50
*
At a glance
- Originator XOMA
- Class Antiacnes; Antibacterials; Antifungals
- Mechanism of Action Endotoxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Bacterial infections; Impetigo
- Discontinued Acne; Mycoses
Most Recent Events
- 24 Jul 2008 Phase-II clinical trials in Impetigo in USA (Topical)
- 14 May 2008 Preclinical trials in Bacterial infections in USA (unspecified route)
- 07 Sep 2006 XOMA is conducting preclinical optimisation studies of a reformulated topical XOMA 629 product for the treatment of mild-to-moderate acne in USA